WEST Search History

DATE: Tuesday, March 18, 2003

Set Name side by side	Query	Hit Count	Set Name result set
DB = USPT, B	PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=ADJ		
L4	9709451.0	0	L4
L3	L2 and (chromoglycate or chromone)	3	L3
L2	hewlett.as.	32896	L2
L1	wigmore.inv.	18	L1

END OF SEARCH HISTORY

WEST Search History

DATE: Tuesday, March 18, 2003

· 	Hit Count	Set Name result set
SPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=ADJ		
112 and (cromoglycate or chromone or chromoglycate or cromone)	2	L13
6200602	5	L12
L10 and (surfactant)	54	L11
L9 and (tablet or pellet)	236	L10
L7 and (coated or coat or coating or enteric)	280	L9
L7 and (sodium)	636	L8
L6 and (oral or orally)	694	L7
L5 and (allergic or allergy)	1007	L6
(cromoglycate or chromone or chromoglycate or cromone)	2428	L5
9709451.0	0	L4
L2 and (chromoglycate or chromone)	3	L3
hewlett.as.	32896	L2
wigmore.inv.	18	L1
	6200602 L10 and (surfactant) L9 and (tablet or pellet) L7 and (coated or coat or coating or enteric) L7 and (sodium) L6 and (oral or orally) L5 and (allergic or allergy) (cromoglycate or chromone or chromoglycate or cromone) 9709451.0 L2 and (chromoglycate or chromone) hewlett.as.	SPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=ADJ 112 and (cromoglycate or chromone or chromoglycate or cromone) 6200602 L10 and (surfactant) L9 and (tablet or pellet) L7 and (coated or coat or coating or enteric) L7 and (sodium) C36 L6 and (oral or orally) L5 and (allergic or allergy) (cromoglycate or chromone or chromoglycate or cromone) 2428 9709451.0 0 L2 and (chromoglycate or chromone) 3 hewlett.as.

END OF SEARCH HISTORY

WEST

Generate Collection

L9: Entry 119 of 119

File: DWPI

Jun 20, 1979

DERWENT-ACC-NO: 1979-47157B

DERWENT-WEEK: 197926

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Tablet contg. cromoglycate and effervescent couple - for treating allergic

conditions in the stomach and intestines

PATENT-ASSIGNEE:

ASSIGNEE CODE FISONS LTD FISO

PRIORITY-DATA: 1977GB-0053825 (December 23, 1977)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
BE 872918 A	June 20, 1979	•	000	
CA 1108992 A	September 15, 1981		000	
CH 641349 A	February 29, 1984		000	
DE 2855001 A	July 5, 1979		000	
DK 7805682 A	July 16, 1979		000	-
FI 7803897 A	August 31, 1979		000	
FR 2412310 A	August 24, 1979		000	
GB 1595220 A	August 12, 1981		000	
IL 56239 A	February 23, 1983		000	
JP 54089016 A	July 14, 1979		000	
NL 7812344 A	June 26, 1979		000	
SE 7813062 A	July 23, 1979		000	
ZA 7807155 A	November 7, 1979		000	

INT-CL (IPC): A61K 9/20; A61K 31/35; A61K 33/00; C07D 311/22

ABSTRACTED-PUB-NO: BE 872918A

BASIC-ABSTRACT:

Tablet for swallowing comprises 5-80 (esp. 35-65) wt.% 1,3-bis (2-carboxychromon-5-yloxy)-2-hydroxypropane (I) or one of its pharmaceutically acceptable salts, and 20-95 wt.% of a mixt. of an alkali or alkaline earth (bi) carbonate and citric acid. The tablet has relative equilibrated humidity <25% and breaks up in the presence of gastro-intestinal fluids.

Pref. (I) is uses as its di Na salt, and the <u>tablet</u> contains 25-35 wt.% Na or K (bi) carbonate and 15-55 wt.% citric acid. Esp. <u>tablets</u> weigh <1g, best 0.2-0.5g and have disintegration time (after BP 1973) 1-15, esp. 3-10 min.

The <u>tablets</u> are used to treat conditions of the stomach or gastro-intestinal tract associated with allergic or immune reactions (e.g. Crohn's disease, ulcerative colitis or atrophic gastritis). The <u>tablets</u> reliably release (I) without problems caused by conversion to the insoluble free acid. (I) is brown for treatment of asthma when administered by inhalation.

TITLE-TERMS: TABLET CONTAIN CROMOGLYCATE EFFERVESCENT COUPLE TREAT ALLERGIC CONDITION STOMACH INTESTINAL

ADDL-INDEXING-TERMS:

ASTHMA

DERWENT-CLASS: B05

CPI-CODES: B05-A01A; B05-A01B; B05-C04; B06-A01; B10-C02; B12-D02; B12-J01; B12-M11;

CHEMICAL-CODES:

Chemical Indexing M2 *01*

Fragmentation Code

A111 A940 C730 C101 C108 C106 C803 C802 C807 C805 C801 A119 C530 A212 A220 M431 M782 R031 R032 R033

R034 R036 R038 R043 M411 M902

Chemical Indexing M2 *02*

Fragmentation Code

J1 H4 J5 H5 M313 M314 M332 M321 M280 M343

M380 M391 D120 D299 J112 J113 H401 H481 J522 H541

H542 M630 M431 M512 M513 M520 P431 P433 P733 M530

M540 P738 P710 M782 R031 R032 R033 R034 R036 R038

R043 M412 M902 D199

Chemical Indexing M2 *03*

Fragmentation Code

J1 H4 M313 M314 M332 M321 M280 M344 M380 M391

J172 J173 H401 H481 M620 M431 M510 M520 M530 M540

M782 R031 R032 R033 R034 R036 R038 R043 M416 M902

Chemical Indexing M6 *04*

Fragmentation Code

R044 R038 R111 R280 R001 P431 P433 P733 P738 P710

M902

WEST

Generate Collection

L1: Entry 2191 of 2199

File: DWPI

Feb 25, 1993

DERWENT-ACC-NO: 1993-067903

DERWENT-WEEK: 199309

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Base for cosmetic and pharmaceutical preparations - comprises microcrystalline cellulose@, silicon di:oxide, lipophilic oil, fat or wax and opt. acrylate! polymer

Basic Abstract Text (2):

A microcrystalline cellulose of mol. wt. 20000-80000 and particle size 1-100 microns e.g, Avicel (RTM), is pref. used. Silicon dioxide is pref. Aerosil (RTM). Lipophilic component is pref. paraffin oil or wax, hemp or flax wax beeswax, a silicon oil, cetyl palmitate or stearate, a mono-, di- or triglyceride, a fatty acid or alcohol, or montan wax.



(51) Int. Cl.5:

(9) BUNDESREPUBLIK DEUTSCHLAND

① Offenlegungsschrift② DE 41 27 665 A 1

A 61 K 47/44 // (A61K 47/44, 47:38) A61K 47:32, 47:04



DEUTSCHES PATENTAMT

(21) Aktenzeichen: P 41 27 665.5
 (22) Anmeldetag: 22. 8. 91
 (33) Offenlegungstag: 25. 2. 93

(1) Anmelder:

Beiersdorf AG, 2000 Hamburg, DE

② Erfinder:

Heinze, Friedrich, Dr., 2000 Hamburg, DE; Wischniewski, Martin, Dr., 3016 Seelze, DE

Für die Beurteilung der Patentfähigkeit in Betracht zu ziehende Druckschriften:

US 47 08 874 A
US 45 22 804 A
US 45 21 402 A
EP 4 30 287 A2
EP 2 75 224 A2
EP 1 20 118 A1
EP 1 08 218 A2

(54) Galenische Matrix

G Galenische Matrices, enthaltend Zusammensetzungen aus (a) Mikrokristalliner Cellulose,

(b) hochdispersem Siliciumdioxid,

(c) wenigstens einen lipophilen Bestandteil, gewählt aus der Gruppe der Öle, Fette und Wachse sowie

(d) gegebenenfalls Acrylatpolymeren und/oder -copolymeren.

sowie gegebenenfalls einen oder mehrere kosmetische oder pharmazeutische Wirkstoffe.